Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Zhou, Xiaohong ^a,b   Evans, Sean L ^b   Han, Xue ^a,b   Liu, Yayan ^b   Yu, Xiao Fang ^a,b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; CULLIN; CULLIN5; ELONGIN B; UNCLASSIFIED DRUG; VIF PROTEIN;

ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; IMMUNOBLOTTING; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN RNA BINDING; PROTEIN STABILITY; PROTEIN TARGETING; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; CORE BINDING FACTOR BETA SUBUNIT; CULLIN PROTEINS; GENE EXPRESSION; HUMANS; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; MUTATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; SOLUBILITY; TRANSCRIPTION FACTORS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84859119983     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033495     Document Type: Article

References (90)

1. Malim MH, Emerman M, (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388-398.
2. Chiu YL, Greene WC, (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26: 317-353.
3. Hache G, Mansky LM, Harris RS, (2006) Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev 8: 148-157.
4. Niewiadomska AM, Yu XF, (2009) Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr Top Microbiol Immunol 339: 1-25.
5. Cullen BR, (2006) Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80: 1067-1076.
6. Goila-Gaur R, Strebel K, (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5: 51.
7. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
8. Luo K, Liu B, Xiao Z, Yu Y, Yu X, et al. (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 78: 11841-11852.
9. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD, (2004) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 78: 12058-12061.
10. Alce TM, Popik W, (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 279: 34083-34086.
11. Douaisi M, Dussart S, Courcoul M, Bessou G, Vigne R, et al. (2004) HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem Biophys Res Commun 321: 566-573.
12. Schafer A, Bogerd HP, Cullen BR, (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328: 163-168.
13. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, et al. (2004) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279: 33177-33184.
14. Navarro F, Bollman B, Chen H, Konig R, Yu Q, et al. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333: 374-386.
15. Burnett A, Spearman P, (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J Virol 81: 5000-5013.
16. Wang T, Tian C, Zhang W, Luo K, Sarkis PT, et al. (2007) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol 81: 13112-13124.
17. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279: 35822-35828.
18. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, et al. (2005) Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 79: 5870-5874.
19. Lecossier D, Bouchonnet F, Clavel F, Hance AJ, (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300: 1112.
20. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
21. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
22. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
23. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif. Cell 114: 21-31.
24. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442.
25. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32: 2421-2429.
26. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L, (2006) Inhibition of Formula-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 Replication. J Virol 80: 11710-11722.
27. Bishop KN, Holmes RK, Malim MH, (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80: 8450-8458.
28. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81: 7099-7110.
29. Luo K, Wang T, Liu B, Tian C, Xiao Z, et al. (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol 81: 7238-7248.
30. Kaiser SM, Emerman M, (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol 80: 875-882.
31. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR, (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 79: 10978-10987.
32. Yang B, Chen K, Zhang C, Huang S, Zhang H, (2007) Virion-associated Uracil DNA Glycosylase-2 and Apurinic/Apyrimidinic Endonuclease Are Involved in the Degradation of APOBEC3G-edited Nascent HIV-1 DNA. J Biol Chem 282: 11667-11675.
33. Yang Y, Guo F, Cen S, Kleiman L, (2007) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365: 92-100.
34. Luo K, Ehrlich E, Xiao Z, Zhang W, Ketner G, et al. (2007) Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. Faseb J 21: 1742-1750.
35. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
36. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D, (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 18: 2861-2866.
37. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591-601.
38. Marin M, Rose KM, Kozak SL, Kabat D, (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
39. Conticello SG, Harris RS, Neuberger MS, (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13: 2009-2013.
40. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
41. Liu B, Yu X, Luo K, Yu Y, Yu XF, (2004) Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 78: 2072-2081.
42. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF, (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 79: 9579-9587.
43. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF, (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18: 2867-2872.
44. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, et al. (2005) Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A 102: 11444-11449.
45. Mehle A, Thomas ER, Rajendran KS, Gabuzda D, (2006) A Zinc-binding Region in Vif Binds Cul5 and Determines Cullin Selection. J Biol Chem 281: 17259-17265.
46. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, et al. (2006) Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349: 290-299.
47. Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, et al. (2007) Characterization of a Novel Cullin5 Binding Domain in HIV-1 Vif. J Mol Biol 373: 541-550.
48. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1: e6.
49. Tian C, Yu X, Zhang W, Wang T, Xu R, et al. (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 80: 3112-3115.
50. Schrofelbauer B, Senger T, Manning G, Landau NR, (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 80: 5984-5991.
51. Russell RA, Pathak VK, (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81: 8201-8210.
52. Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, et al. (2007) Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 81: 13235-13241.
53. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Opi S, et al. (2008) HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372: 136-146.
54. Goila-Gaur R, Khan MA, Miyagi E, Strebel K, (2008) Differential Sensitivity of "Old" versus "New" APOBEC3G to Human Immunodeficiency Virus Type-1 Vif. J Virol.
55. He Z, Zhang W, Chen G, Xu R, Yu XF, (2008) Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol 381: 1000-1011.
56. Chen G, He Z, Wang T, Xu R, Yu XF, (2009) A patch of positively charged amino acids surrounding the HIV-1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol.
57. Zhang W, Huang M, Wang T, Tan L, Tian C, et al. (2008) Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol 10: 1662-1675.
58. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF, (2008) Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS ONE 3: e3963.
59. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, et al. (2008) Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 82: 8656-8663.
60. Reingewertz TH, Benyamini H, Lebendiker M, Shalev DE, Friedler A, (2009) The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. Protein Eng Des Sel 22: 281-287.
61. Giri K, Maynard EL, (2009) Conformational analysis of a peptide approximating the HCCH motif in HIV-1 Vif. Biopolymers 92: 417-425.
62. Giri K, Scott RA, Maynard EL, (2009) Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif. Biochemistry 48: 7969-7978.
63. Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y, (2010) Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J Virol 84: 7135-7139.
64. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, et al. (2010) The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 6: e1000925.
65. Gallerano D, Devanaboyina SC, Swoboda I, Linhart B, Mittermann I, et al. (2011) Biophysical characterization of recombinant HIV-1 subtype C virus infectivity factor. Amino Acids 40: 981-989.
66. Marcsisin SR, Engen JR, (2010) Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif. J Mol Biol 402: 892-904.
67. Barraud P, Paillart JC, Marquet R, Tisne C, (2008) Advances in the structural understanding of Vif proteins. Curr HIV Res 6: 91-99.
68. Marcsisin SR, Narute PS, Emert-Sedlak LA, Kloczewiak M, Smithgall TE, et al. (2011) On the solution conformation and dynamics of the HIV-1 viral infectivity factor. J Mol Biol 410: 1008-1022.
69. Yang X, Goncalves J, Gabuzda D, (1996) Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem 271: 10121-10129.
70. Bernacchi S, Mercenne G, Tournaire C, Marquet R, Paillart JC, (2011) Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res 39: 2404-2415.
71. Sorensen HP, Mortensen KK, (2005) Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact 4: 1.
72. Zhang W, Du J, Evans SL, Yu Y, Yu XF, (2012) T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481: 376-379.
73. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, et al. (2012) Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481: 371-375.
74. Jager S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, et al. (2012) Global landscape of HIV-human protein complexes. Nature 481: 365-370.
75. Hultquist JF, Binka M, Larue RS, Simon V, Harris RS, (2011) Vif Proteins of Human and Simian Immunodeficiency Viruses Require Cellular CBFbeta to Degrade APOBEC3 Restriction Factors. J Virol.
76. Hwang BJ, Liao JC, Chu G, (1996) Isolation of a cDNA encoding a UV-damaged DNA binding factor defective in xeroderma pigmentosum group E cells. Mutat Res 362: 105-117.
77. Hajra A, Collins FS, (1995) Structure of the leukemia-associated human CBFB gene. Genomics 26: 571-579.
78. Huang X, Crute BE, Sun C, Tang YY, Kelley JJ 3rd, et al. (1998) Overexpression, purification, and biophysical characterization of the heterodimerization domain of the core-binding factor beta subunit. J Biol Chem 273: 2480-2487.
79. Zhang H, Pomerantz RJ, Dornadula G, Sun Y, (2000) Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol 74: 8252-8261.
80. Khan MA, Aberham C, Kao S, Akari H, Gorelick R, et al. (2001) Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol 75: 7252-7265.
81. Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R, (2007) RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J Biol Chem 282: 26361-26368.
82. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF, (2000) Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol 74: 8938-8945.
83. de Bruijn MF, Speck NA, (2004) Core-binding factors in hematopoiesis and immune function. Oncogene 23: 4238-4248.
84. Ito Y, (2008) RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 99: 33-76.
85. Reingewertz TH, Shalev DE, Friedler A, (2010) Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure. Protein Pept Lett 17: 988-998.
86. Bravo J, Li Z, Speck NA, Warren AJ, (2001) The leukemia-associated AML1 (Runx1)-CBF beta complex functions as a DNA-induced molecular clamp. Nat Struct Biol 8: 371-378.
87. Yang S, Sun Y, Zhang H, (2001) The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem 276: 4889-4893.
88. Yang B, Gao L, Li L, Lu Z, Fan X, et al. (2003) Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem 278: 6596-6602.
89. Miller JH, Presnyak V, Smith HC, (2007) The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4: 81.
90. Auclair JR, Green KM, Shandilya S, Evans JE, Somasundaran M, et al. (2007) Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 69: 270-284.